• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Laser-activated deep-sea drug kills prostate cancer

December 20, 2016 By Sarah Faulkner

Study: Laser-activated deep-sea drug kills prostate cancerResearchers from the Weizmann Institute of Science and Steba Biotech have reportedly developed a light-sensitive drug derived from deep-sea bacteria that has been shown to kill cancer cells in low-risk prostate cancer patients without affecting healthy tissue. The team’s work was published in Lancet Oncology.

Vascular-targeted photodynamic therapy, VTP, utilizes a drug called WST11 which was derived from bacteria that survive with very little sunlight at the bottom of the ocean. The bacteria have evolved to efficiently convert light into energy. This property enables WST11 to release free radicals and kill surrounding cells when exposed to a laser light.

“These results are excellent news for men with early localised prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,” lead researcher Mark Emberton said, according to Reuters. “This is truly a huge leap forward.”

The trial enrolled 413 patients at 47 treatment sites across 10 European countries. Half of the patients who received VTP went into remission, while 13.5% of the control group went into remission.

Normally, men with low-risk prostate cancer are actively observed by their doctors and only treated when the cancer progresses. High-risk cancer patients sometimes undergo radical therapy, surgically removing or irradiating the prostate, which can cause lifelong erectile problems and incontinence.

The researchers found that VTP only caused short-term urinary and erectile problems and that no significant side effects remained after 2 years. Just 6% of patients who received VTP required radical therapy, compared to 30% of the patients in the control arm.

The European Medicines Agency is reviewing VTP as a possible treatment method for low-risk prostate cancer patients, but the process is expected to take several years.

Filed Under: Featured, Oncology, Research & Development Tagged With: Steba Biotech, Weizmann Institute of Science

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS